Chemotherapy for Advanced Biliary System Cancer
Author Information
Author(s): O Nehls, B Klump, H T Arkenau, H G Hass, A Greschniok, M Gregor, R Porschen
Primary Institution: University Hospital, Tübingen, Germany
Hypothesis
Does the combination of oxaliplatin and fluorouracil-leucovorin improve outcomes in patients with advanced biliary system adenocarcinomas?
Conclusion
The combination of oxaliplatin and fluorouracil-leucovorin shows promise in treating advanced biliary adenocarcinomas, with a disease control rate of 56% and a median overall survival of 9.5 months.
Supporting Evidence
- The disease control rate was 56%, indicating some patients responded to the treatment.
- The median overall survival time was 9.5 months, which is an improvement over previous treatments.
- No toxic deaths occurred during the study, suggesting the treatment was safe.
Takeaway
This study tested a new chemotherapy combination for patients with a serious type of cancer, and it helped some patients live longer.
Methodology
This was a prospective multicentre study involving 16 patients with advanced biliary tract adenocarcinomas who received a specific chemotherapy regimen.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Patients had histologically or cytologically confirmed adenocarcinomas of the gallbladder or biliary tract.
Statistical Information
Confidence Interval
95% CI, 29–84%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website